The Acceptance of Bitcoin, and These Other Select Cryptocurrencies, Will Improve the Company’s Ability to Transact with Its Global Customer Base
NEW YORK, NY, Feb. 12, 2021 (GLOBE NEWSWIRE) – – through NewMediaWire – – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga†or the “Companyâ€), an income creating, enhanced life sciences organization, with a restrictive line of CBD and CBG mixed Supplement biting gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as a continuous Pharmaceutical Development drive, today reported that it is currently arranged to acknowledge the accompanying digital forms of money as installment choices on its E-Commerce Platform (www.taurigum.com): Bitcoin (“BTCâ€), Etherium (“ETHâ€), Bitcoin Cash (“BCHâ€), Dai (“DAIâ€), and Litecoin (“LTCâ€). As the Company keeps on developing its client base, it is critical to be basically as accommodative as conceivable to the necessities of its clients — across the globe.   Â
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (TAUG) is an income creating, expanded life sciences organization, occupied with a few significant business exercises and initiatives. The organization fabricates and conveys a few restrictive retail items and product offerings, basically centered around the Cannabidiol (“CBDâ€) and Cannabigerol (“CBGâ€) Edibles market segment.  The fundamental product offering, marked as Tauri-Gumâ„¢, comprises of an exclusive enhancement biting gum that is Kosher guaranteed, Halal affirmed, and Vegan Formulated (CBD Infused Tauri-Gumâ„¢ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gumâ„¢ Flavors: Peach-Lemon, Black Currant) and (Vitamin C + Zinc “Immune Booster†Flavor: Pear Bellini).  The Company’s commercialization methodology comprises of a wide cluster of retail clients, wholesalers, and a quickly developing E-Commerce business fragment (E-Commerce site: www.taurigum.com). If it’s not too much trouble, visit our corporate site, for extra data, as well as requests, at http://www.tauriga.com
Complementary to the Company’s retail business, is its continuous Pharmaceutical Development initiative.â This connects with the improvement of a proposed Pharmaceutical grade variant of Tauri-Gumâ„¢, for sickness guideline (explicitly intended for the accompanying sign: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company declared that it had recorded a temporary U.S. patent application covering its drug grade adaptation of Tauri-Gumâ„¢.â The Patent, recorded with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENTâ€. On December 18, 2020, the Company revealed that it had gone into a Master Services Agreement with CSTI to lead the Company
